61
Participants
Start Date
April 7, 2014
Primary Completion Date
January 25, 2016
Study Completion Date
April 19, 2018
Talimogene laherparepvec
Talimogene laherparepvec will be administered by intralesion injection at an initial dose of up to 4.0 mL of 10\^6 PFU/mL. The second and subsequent doses will will be up to 4.0 mL 10\^8 PFU/mL. The second dose should be administered 21 days from the initial dose. All subsequent doses should be given every 14 days.
Research Site, Winston-Salem
Research Site, Tampa
Research Site, Germantown
Research Site, Louisville
Research Site, Indianapolis
Research Site, Minneapolis
Research Site, Fridley
Research Site, Dallas
Research Site, Salt Lake City
Research Site, Albuquerque
Research Site, New Brunswick
Research Site, Calgary
Research Site, Edmonton
Research Site, Montreal
Lead Sponsor
Amgen
INDUSTRY